黑料网

Cancer treatment; Immunotherapy System; Immune system

Introduction

The principles of immunotherapy

The immune system is a complex network of cells, tissues, and organs that work together to defend the body against infections, diseases, and abnormal cells, including cancer cells. Cancer cells often find ways to evade or suppress the immune system, allowing them to grow and spread unchecked. Immunotherapy aims to restore or enhance the immune system's ability to recognize and destroy cancer cells.

Materials and Methods

Mechanisms of immunotherapy

Immunotherapy employs different mechanisms to engage the immune system in the fight against cancer. Some common approaches include:

1. Checkpoint inhibitors: Cancer cells can exploit "checkpoints" on immune cells, which regulate immune responses, to evade detection and attack. Checkpoint inhibitors block these checkpoints, such as PD-1 or CTLA-4, to release the brakes on the immune system, allowing it to recognize and attack cancer cells more effectively.

2. CAR-T cell therapy: Chimeric Antigen Receptor (CAR) T-cell therapy involves modifying a patient's own T cells genetically to express a receptor that recognizes specific cancer cells. Once infused back into the patient, these engineered T cells can target and destroy cancer cells.

3. Immune-modulating antibodies: Antibodies can be engineered to directly target cancer cells or modulate immune responses. Monoclonal antibodies can bind to specific antigens on cancer cells, marking them for destruction by immune cells. Other antibodies can stimulate immune cells or enhance immune responses.

4. Cancer vaccines: Cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. They can be preventive, targeting cancer-causing viruses or early cancer cells, or therapeutic, enhancing the immune response against existing cancer cells[1-9].

5. Adoptive cell transfer: Adoptive cell transfer involves harvesting and expanding immune cells from the patient, such as tumor-infiltrating lymphocytes (TILs), and reintroducing them back into the patient after activation or genetic modification to enhance their cancer-fighting abilities.

Results and Discussion

Impact and success of immunotherapy

Immunotherapy has demonstrated remarkable success in the treatment of various cancers. It has revolutionized the management of metastatic melanoma, lung cancer, kidney cancer, and other malignancies, significantly improving patient outcomes. Some patients who previously had limited treatment options have experienced durable responses and even long-term remission with immunotherapy.

Immunotherapy advancements and challenges

The field of immunotherapy continues to evolve rapidly. Ongoing research focuses on expanding the range of cancers that can benefit from immunotherapy, identifying predictive biomarkers to select patients likely to respond, and improving treatment efficacy and safety. Combination therapies, such as combining immunotherapy with chemotherapy or targeted therapy, are being explored to enhance treatment responses.

Despite the remarkable success, challenges remain in immunotherapy. Not all patients respond to immunotherapy, and resistance can develop over [1-6] time. Adverse effects, such as immunerelated toxicities, require careful monitoring and management. Additionally, the high cost of immunotherapy remains a barrier to access for some patients.

Several factors can influence the effectiveness and outcomes of immunotherapy in cancer treatment. Understanding these factors is crucial for optimizing patient selection, treatment planning, and therapeutic success. Here are some key factors that can impact immunotherapy

Tumor type and characteristics: Different tumor types exhibit varying levels of immunogenicity, or the ability to provoke an immune response. Some tumors have a higher mutational burden or express specific antigens that make them more susceptible to immunotherapy. Tumors with a higher number of infiltrating immune cells, known as tumor-infiltrating lymphocytes (TILs), often respond better to immunotherapy. Additionally, the presence of specific molecular markers or genetic alterations within the tumor can impact immunotherapy response.

Immune microenvironment: The immune Table 1 microenvironment within the tumor plays a critical role in immunotherapy response. Factors such as the presence of immunesuppressive cells, cytokines, and other molecules can create an immunosuppressive environment that hampers the immune system's ability to mount an effective response against cancer cells. Conversely, an inflamed or immune-active microenvironment characterized by the presence of activated immune cells can enhance immunotherapy efficacy.

Table 1: Not all patients respond to immunotherapy, and resistance can develop over time.

Biomarkers and predictive factors: Biomarkers and predictive factors are essential for identifying patients who are more likely to respond to immunotherapy. For example, the expression of programmed death-ligand 1 (PD-L1) on tumor cells or the tumor mutational burden (TMB) can serve as predictive biomarkers for response to immune checkpoint inhibitors. Other factors, such as specific genetic alterations or immune-related gene signatures, may also be indicative of immunotherapy response.

Immune system function: The overall function and health of a patient's immune system can impact the effectiveness of immunotherapy. Patients with compromised immune systems, such as those with certain autoimmune diseases or those who have received extensive prior immunosuppressive treatments, may have reduced responses to immunotherapy. Conversely, patients with a robust and active immune system may be more likely to benefit from immunotherapy.

Treatment timing and sequence: The timing and sequence of immunotherapy in relation to other treatments, such as surgery, chemotherapy, or radiation therapy, can influence its efficacy. Combining immunotherapy with other treatment modalities in a synergistic manner or administering immunotherapy as adjuvant therapy following surgery can enhance its effectiveness.

The future of immunotherapy holds immense promise as researchers continue to make groundbreaking discoveries and advancements in the field. Here are some potential areas of future growth and development in immunotherapy:

Combination therapies: Combination approaches involving immunotherapy and other treatment modalities, such as targeted therapy, chemotherapy, or radiation therapy, are being extensively explored. The goal is to enhance treatment response and overcome resistance mechanisms by leveraging the complementary mechanisms of different therapies. Novel combinations and sequencing strategies are being investigated to improve outcomes across a wide range of cancer types.

Personalized medicine: The concept of personalized medicine is gaining momentum in immunotherapy. Identifying predictive biomarkers and molecular signatures that can accurately stratify patients based on their likelihood of response to immunotherapy is crucial. This includes the development of diagnostic tools to assess tumor immunogenicity and predict treatment outcomes. Precision medicine approaches will enable tailoring treatment strategies to individual patients, maximizing the chances of successful outcomes.

Novel immune targets: While immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have been successful, there is ongoing research to identify new immune targets and develop innovative immunotherapies. Targeting other checkpoint molecules, such as LAG-3, TIM-3, or TIGIT, is being explored. Additionally, discovering new tumor-specific antigens or neoantigens and designing therapies to target them can further enhance the effectiveness of immunotherapy.

Cellular therapies: CAR-T cell therapy, which has shown remarkable success in hematological malignancies, is being expanded to solid tumors. Advancements in CAR design, including the development of multi-specific CARs and armored CARs, are being pursued to improve target recognition and persistence of CAR-T cells. Other cellular therapies, such as natural killer (NK) cell-based immunotherapies and engineered T-cell receptor (TCR) therapies, are also being investigated.

Overcoming resistance: Resistance to immunotherapy remains a challenge. Understanding the mechanisms underlying resistance and developing strategies to overcome it are crucial. Research is focused on identifying biomarkers of resistance, exploring combination approaches to tackle resistance pathways, and developing therapies that enhance immune cell function or reverse immunosuppression within the tumor microenvironment.

Conclusion

Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to combat cancer cells. It offers new hope for patients, with improved treatment outcomes and the potential for long-term remission. As research and advancements continue, immunotherapy is expected to expand its reach and impact even more cancer types. With ongoing efforts to address challenges and improve patient selection and safety, immunotherapy holds great promise in the fight against cancer, paving the way for a future where personalized and immune-based treatments become the standard of care. Despite its success, challenges exist in the field of immunotherapy. Not all patients respond to immunotherapy, and resistance can develop over time. Adverse effects, known as immunerelated toxicities, require careful monitoring and management. Additionally, the cost of immunotherapy poses barriers to widespread accessibility. In conclusion, immunotherapy represents a paradigm shift in cancer treatment, utilizing the body's immune system to fight cancer. Its success in various malignancies has transformed patient outcomes and offers hope for those with limited treatment options. Ongoing research and advancements aim to optimize immunotherapy approaches, overcome challenges, and extend its benefits to a broader range of cancers. Immunotherapy continues to shape the future of cancer treatment, driving towards personalized and immunebased therapies that hold the potential for long-term remission and improved quality of life for patients. In conclusion, immunotherapy has emerged as a groundbreaking and transformative approach in cancer treatment. By harnessing the power of the immune system, immunotherapy offers new hope for patients battling various types of cancer. The success of immunotherapy in achieving durable responses and long-term remission has revolutionized the management of malignancies that were once considered difficult to treat. The principles of immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapy, immune-modulating antibodies, cancer vaccines, and adoptive cell transfer, have demonstrated remarkable efficacy in specific cancer types. Immunotherapy has significantly improved patient outcomes, providing a potential cure or long-term disease control for many individuals.

However, challenges and areas for further improvement exist. Not all patients respond to immunotherapy, and mechanisms of resistance can develop over time. Adverse effects, known as immunerelated toxicities, require careful monitoring and management.

Additionally, the high cost of immunotherapy remains a barrier to widespread accessibility. While challenges remain, the future of immunotherapy is bright, offering hope for patients and the potential for transformative advancements in the field of oncology. Continued research, collaboration, and investment will drive the progress of immunotherapy, bringing us closer to more effective, personalized, and accessible treatments for cancer patients worldwide.

Acknowledgements

The University of Nottingham provided the tools necessary for the research, for which the authors are thankful.

Conflict of Interest

For the research, writing, and/or publication of this work, the authors disclosed no potential conflicts of interest.

1. Doherty R, Madigan S, Warrington G, Ellis J (2019) Nutrients 11:822.

, ,

2. Jagannath A, Taylor L, Wakaf Z, Vasudevan SR, Foster RG, et al. (2017) Hum Mol Genet 26:128-138.

, ,

3. Somberg J (2009) Am J Ther 16: 281-282.

,

4. Wahner-Roedler DL, Knuth P, Juchems RH (1997) Mayo Clin Proc72: 1061-1068.

, ,

5. Nally MC (2009) J Clin Invest119: 1-10.

, ,

6. Weinstein JN (2016) Spine41: 1-2.

, ,

7. Marshall E C (1989) Assurance of quality vision care in alternative health care delivery systems. J Am Optom Assoc 60: 827-831.

,

8. Cutler (2021) Building health care better means reining in costs. In JAMA Health Forum 2: 210117-210117.

, ,

9. Lindeque BG (2009) Orthopedics 32: 551.

, ,